These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 18232530)

  • 1. [Still questions around the slimming agent rimobant. Not approved in USA because of the risk of mental adverse effects].
    Wettermark B; Raaschou P; Forslund T; Hjemdahl P
    Lakartidningen; 2007 Dec; 104(51-52):3879-81. PubMed ID: 18232530
    [No Abstract]   [Full Text] [Related]  

  • 2. [Cannabinoid receptor blocker rimonabant. CNS side effects prevent U.S. approval].
    MMW Fortschr Med; 2007 Jun; 149(27-28):8. PubMed ID: 17717874
    [No Abstract]   [Full Text] [Related]  

  • 3. Depression and weight loss: opposite outcome for surgery and rimonabant?
    Chaput JP; Tremblay A
    Obes Rev; 2008 Sep; 9(5):504-7. PubMed ID: 18643944
    [No Abstract]   [Full Text] [Related]  

  • 4. Rimonabant, obesity and diabetes.
    Prescrire Int; 2007 Jun; 16(89):122. PubMed ID: 17585427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impairments in endocannabinoid signaling and depressive illness.
    Hill MN; Gorzalka BB
    JAMA; 2009 Mar; 301(11):1165-6. PubMed ID: 19293417
    [No Abstract]   [Full Text] [Related]  

  • 6. Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks.
    Gadde KM; Allison DB
    Circulation; 2006 Aug; 114(9):974-84. PubMed ID: 16940206
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy and safety of the weight-loss drug rimonabant.
    Després JP; Van Gaal L; Pi-Sunyer X; Scheen A
    Lancet; 2008 Feb; 371(9612):555; author reply 556-7. PubMed ID: 18280320
    [No Abstract]   [Full Text] [Related]  

  • 8. [Antiobesity drugs--new limitations].
    Nau JY
    Rev Med Suisse; 2007 Nov; 3(135):2753. PubMed ID: 18214233
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of rimonabant on weight and cardiometabolic risk factors.
    Gadde KM
    JAMA; 2006 Aug; 296(6):649-50; author reply 650-1. PubMed ID: 16896103
    [No Abstract]   [Full Text] [Related]  

  • 10. New diet drug stirs high hopes. But can the pill, rimonabant, liver up to large expectations?
    Heart Advis; 2005 Feb; 8(2):3. PubMed ID: 15806687
    [No Abstract]   [Full Text] [Related]  

  • 11. [Rimonabant. Risk of depression has not been finally clarified].
    Kreutzkamp B
    Med Monatsschr Pharm; 2008 May; 31(5):191-2. PubMed ID: 18552079
    [No Abstract]   [Full Text] [Related]  

  • 12. Rimonabant induces partial seizures in a patient with a history of generalized epilepsy.
    Braakman HM; van Oostenbrugge RJ; van Kranen-Mastenbroek VH; de Krom MC
    Epilepsia; 2009 Sep; 50(9):2171-2. PubMed ID: 19706063
    [No Abstract]   [Full Text] [Related]  

  • 13. The cardiometabolic drug rimonabant: after 2 years of RIO-Europe and STRADIVARIUS.
    Kintscher U
    Eur Heart J; 2008 Jul; 29(14):1709-10. PubMed ID: 18556715
    [No Abstract]   [Full Text] [Related]  

  • 14. [2008: the end of rimonabant's story].
    Paris M
    Ann Pharm Fr; 2009 May; 67(3):167-8. PubMed ID: 19446664
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.
    Després JP; Golay A; Sjöström L;
    N Engl J Med; 2005 Nov; 353(20):2121-34. PubMed ID: 16291982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rimonabant: suicide and depression. Depression and suicidal tendencies are about twice as frequent with rimonabant as with placebo.
    Prescrire Int; 2007 Dec; 16(92):250. PubMed ID: 18092422
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacotherapy for obesity--promise and uncertainty.
    Yanovski SZ
    N Engl J Med; 2005 Nov; 353(20):2187-9. PubMed ID: 16291989
    [No Abstract]   [Full Text] [Related]  

  • 18. [The endocannabinoid system and treatment of obesity].
    Aronsen L
    Tidsskr Nor Laegeforen; 2008 Feb; 128(5):570-1. PubMed ID: 18311201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Depression and anxiety with rimonabant.
    Mitchell PB; Morris MJ
    Lancet; 2007 Nov; 370(9600):1671-2. PubMed ID: 18022023
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials.
    Christensen R; Kristensen PK; Bartels EM; Bliddal H; Astrup A
    Lancet; 2007 Nov; 370(9600):1706-13. PubMed ID: 18022033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.